Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mattheos Bobos

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 26, 2025
Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group studyHelena Linardou, Kyriaki Papadopoulou, Nikolaos Korfiatis, et al.
Plos One|December 7, 2018
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) studyAngelos Koutras, Georgios Lazaridis, Georgia-Angeliki Koliou, et al.
International Journal of Cancer|September 1, 2017
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast EuropeGeorge Fountzilas, Amanda Psyrri, Eleni Giannoulatou, et al.
Breast Cancer Research and Treatment|December 22, 2011
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialHelen Gogas, Urania Dafni, Maria Karina, et al.
Plos One|June 9, 2012
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.
Medical Oncology (Northwood, London, England)|June 2, 2018
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotypingGeorge Papaxoinis, Vassiliki Kotoula, Eleni Giannoulatou, et al.
ESMO Open|June 25, 2019
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancerElena Fountzilas, Vassiliki Kotoula, George Pentheroudakis, et al.
Oncotarget|April 30, 2016
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingGeorge Fountzilas, Eleni Giannoulatou, Zoi Alexopoulou, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2014
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabEvangelia Razis, George Pentheroudakis, George Rigakos, et al.
Plos One|August 11, 2017
Protein expression patterns of cell cycle regulators in operable breast cancerFlora Zagouri, Vassiliki Kotoula, George Kouvatseas, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|August 26, 2025
Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group studyHelena Linardou, Kyriaki Papadopoulou, Nikolaos Korfiatis, et al.
Plos One|December 7, 2018
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) studyAngelos Koutras, Georgios Lazaridis, Georgia-Angeliki Koliou, et al.
International Journal of Cancer|September 1, 2017
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast EuropeGeorge Fountzilas, Amanda Psyrri, Eleni Giannoulatou, et al.
Breast Cancer Research and Treatment|December 22, 2011
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialHelen Gogas, Urania Dafni, Maria Karina, et al.
Plos One|June 9, 2012
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.
Medical Oncology (Northwood, London, England)|June 2, 2018
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotypingGeorge Papaxoinis, Vassiliki Kotoula, Eleni Giannoulatou, et al.
ESMO Open|June 25, 2019
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancerElena Fountzilas, Vassiliki Kotoula, George Pentheroudakis, et al.
Oncotarget|April 30, 2016
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingGeorge Fountzilas, Eleni Giannoulatou, Zoi Alexopoulou, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2014
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabEvangelia Razis, George Pentheroudakis, George Rigakos, et al.
Plos One|August 11, 2017
Protein expression patterns of cell cycle regulators in operable breast cancerFlora Zagouri, Vassiliki Kotoula, George Kouvatseas, et al.
Pageof 10